The small intestine has been called as a dark continent of diges tive tract and it had been very difficult to diagnose or treat the disease of small intestine. However recent technological develop ment including video capsule endoscopy or balloon assisted endoscopy has made us to aware the various diseases of small intestine. By using capsule endoscopy, many researchers reported that more than 70% of patients treated continuously with non steroidal anti inflammatory drugs (NSAID) exhibit the mucosal damage of small intestine. In some cases, NSAID not only causes mucosal damage but also results in life threatening bleeding from small intestine, which had not been prevented or cured by gastro protective drug or anti gastric acid secretion drug administration. Therefore to investigate and identify the effective drug that pro tects small intestine from mucosal damage is urgently expected. In spite of extensive investigation in clinical field, only a few drugs such as misoprostol, a synthetic prostaglandin E1 analogue, has been reported as an effective one but is not satisfactory enough to fulfill the requirement of patients who suffer from NSAID induced mucosal damage of small intestine. And now, extensive study is being performed using several gastro mucoprotective drugs by many researchers. In this review, we introduce the current clinical situation in small intestinal injury of patients under NSAID treatment, and to summarize the molecular mechanism by which NSAID, including acetyl salicylic acid, cause small intestinal damage. In addition, we present results of clinical trials performed so far, and refer the possible preventive method or treatment in the near future.
Introduction T he adverse effects of non-steroidal anti-inflammatory drugs (NSAID) on stomach and duodenum have been intensively investigated. However, these effects on small intestine have not been sufficiently investigated. Recent advance in endoscopic technology enabled us to observe small intestinal mucosa more in detail. By using a balloon assisted endoscopy (BAE), such as a double-or a single-balloon endoscopy (DBE or SBE), and a video capsule endoscopy (VCE), we came to know that NSAID cause mucosal damage also in small intestine with relatively high frequency. By using VCE, Graham et al. (1) have found that patients who took various NSAIDs for more than three months exhibit intestinal mucosal damage, compared to 10% of the individuals who took either acetaminophen alone or nothing as a control group. Maiden et al.
(2) also reported by using VCE that 68% of the 40 healthy volunteers formed intestinal mucosal damage after 14 days medication with diclofenac (a traditional NSAID) and omeprazole (a proton pump inhibitor). In this review, we described the current situation of NSAID-induced intestinal mucosal damage and the molecular mechanism by which NSAID cause intestinal mucosal damage. By clarifying the mechanism together with clinical feature using VCE and BAE, we will be able to find new strategies for preventing NSAID-induced small intestinal damage.
The evaluation method for NSAID induced intestinal mucosal damage and endoscopic features NSAID-induced small intestinal mucosal damage shows various endoscopic features such as small shallow round ulcers, punched out ulcers, ring ulcers, irregular shaped ulcers, longitudinal ulcers, membranous stenosis, perforation and so on. (3) (4) (5) The location of the NSAID-induced injury in the intestinal lumen is not specific. Multiple lesions are often found.
For the diagnosis of NSAID-induced small intestinal mucosal damage, BAE and VCE is thought to be useful. Matsumoto et al. (6) have reported that BAE is as useful method as VCE in evaluating the severity of NSAID-induced small intestinal injury. Although both methods have its advantages and disadvantages, (7) VCE can be a relatively stronger tool than BAE for screening the NSAIDinduced small intestinal injury and evaluating the efficacy of candidate drugs on the treatment or prevention of NSAID-induced small intestinal injury, since VCE is less invasive method than BAE. Since we nowadays have some evaluation criteria for the inflammation and damage of small intestinal mucosa, such as that by Graham et al., (1) Goldstein et al., (8) Maiden et al., (9) and Gralnek et al. (10) (Lewis score), we will be able to evaluate directly and precisely the efficacy of candidate muco-protective drugs on NSAID-induced small intestinal injury by using VCE.
On the other hand, BAE can be a stronger tool than VCE for diagnosis and endoscopic treatment, since BAE enable us to examine the lesion as close as possible, to assess histological findings and to perform endoscopic therapy such as balloon dilation for intestinal stenosis or endoscopic hemostasis for intestinal bleeding. In general, NSAID-induced small intestinal ulcer is shallower than that of Crohn's disease. Therefore, the first line therapy for membranous stenosis formed by NSAID-induced ulcer is endoscopic balloon dilation, (5, 11) whereas in Crohn's disease, the stenosis is formed by deep ulceration and the endoscopic balloon dilation is not always an adequate therapy. As to endoscopic hemostasis, electrocoagulation, clipping, injection therapy is usually selected based on the endoscopic classification of vascular lesions of the small intesitine. (12) Argon plasma coagulation can burn wide surface but shallow layer of small intestinal mucosa and can be safely used for the lesion such as an angioectasia exhibiting small amount of oozing continuously. On the other hand, clipping is mechanically effective method for the actively bleeding angioectasia. Another therapeutic method is injecting sclerosing T agent such as polidocanol (Aethoxysklerol) or ethanolamine oleate around vessels (paravascular injection), (13) however, this indirect hemostasis method is to be examined more in detail.
The molecular mechanism of NSAID induced intestinal damage
Although mechanisms by which NSAID induce intestinal damage are multifactorial and therefore difficult to be clearly classified, cyclooxygenase (COX) seems to be greatly involved in the pathogenesis of NSAID-induced intestinal damage. Therefore, in this section, we classified the molecular mechanism in two categories; COX-dependent mechanism and COX-independent mechanism ( Fig. 1) .
COX dependent mechanism. NSAID inhibit the intramucosal synthesis of prostaglandins (PG) via inhibiting COX activity at inflamed sites, and thus exhibiting analgesic, antipyretic, and anti-inflammatory effects. In the small intestine, PG regulates gastrointestinal blood flow and mucus secretion, exhibiting mucosal protective functions. Therefore, the inhibition of PG production has been thought to be the major cause of NSAIDinduced small intestinal injury. COX has two subtypes; COX-1 and COX-2. Among these COX subtypes, COX-1 mediated-PG synthesis is especially important for maintaining the mucosal homeostasis. The inhibition of COX-1 has been shown to result in the increment of mucosal permeability, the invasion of intestinal bacteria into mucosa and the synthesis of inducible nitric oxide synthase (iNOS). Inhibition of COX-1 has also been shown to result in the inhibition of intestinal mucosal microcirculation, (14) whereas COX-2 plays a role in the production of PGE2 to protect intestinal mucosa.
(15) Therefore COX-1 inhibition is not sufficient for the intestinal mucosal damage. Nowadays, it is widely accepted concept that in addition to the COX-1 inhibition, the COX-2 inhibition is inevitable for the intestinal mucosal damage. (15, 16) COX independent mechanism. As for the COX-independent pathogenic mechanism by which NSAID induce intestinal mucosal damage, Bjarnason et al. (17) proposed "three hit theory". At first, NSAID lyses phospholipids on the mucosal surface and directly injure the mitochondria of intestinal epithelial cells. In the next step, mitochondrial dysfunction results in calcium efflux, free radical formation, reduced intercellular connection, and increased permeability of intestinal mucosa. At the final step, increased intercellular permeability resulted in the intrusion of bile acids, proteases, intestinal bacteria, and toxins that ultimately results in mucosal injury. In addition, Bjarnason et al. (18) concluded that the primary adverse effect of NSAID is to increase the permeability of small intestinal mucosa, and the inflammation or ulcer formation is secondary adverse effect caused by neutrophils that is activated by bile acids or intestinal bacteria.
Recently we have reported that indomethacin (a traditional NSAID) induces reactive oxygen species (ROS) production in mitochondria of small intestinal epithelial cells and apoptosis of these cells that might lead to intestinal mucosal damage (19, 20) that is independent of PG suppression. In addition, this ROS production might interact with the other intracellular molecules to cause further injury. Constitutive NOS (cNOS)-derived nitric oxide (21) by interacting each other. Since NSAID has been reported to undergo entero-hepatic circulation, (22) and Smale et al. (23) emphasized the entero-hepatic circulation of NSAID. They reported that entero-hepatic circulation independent drugs such as sulindac has lower toxicity to small intestinal mucosa. This issue also should be confirmed in further assessment.
Recently many researchers are getting aware of the important role of intestinal bacteria on NSAID-induced small intestinal damage. Accordingly, several groups have reported the importance of the intestinal bacteria as shown in follows. Indomethacin could not cause mucosal damage in germ free rat (24, 25) and some antibiotics such as metronidazole (18) and ampicillin (26) or some probiotics (e.g., lactobacillus casei (27) ) suppressed indomethacininduced intestinal mucosal damage suggesting the pivotal involvement of intestinal bacteria in NSAID-induced mucosal damage. Watanabe et al. (28) reported interesting findings about the active role of toll-like receptor 4 (TLR4) on NSAID-induced small intestinal damage that recognizes lipopolysaccharide (LPS) of gram-negative bacteria and mediates inflammatory activation. They found that indomethacin-and diclofenac-induced intestinal mucosal damage was significantly suppressed in TLR4 mutant mice. This result indicates that NSAID damages intestinal mucosal barriers, causes invasion of gram negative bacteria into mucosa and their LPS activates TLR4 to cause inflammatory reactions such as cytokine production and subsequent chemotaxis of neutrophils. (27) An interesting report has recently been published by Pilotto et al. (29) They suggested that genetic differences might be involved in the increased susceptibility of the small intestinal injury; the polymorphism of CYP2C, an enzyme that metabolizes NSAID, modified the risk of NSAID-related gastroduodenal bleeding. (29) This finding may explain why not all the patients, who are taking NSAID, exhibit the small intestinal damage. This issue should be investigated more in detail with small intestine.
Acetyl salicylic acid induced small intestinal injury
Among NSAID, acetyl salicylic acid (ASA) has a unique property, which exhibits anti-inflammatory effects at high dose and anti-platelet effects at low dose. Therefore, ASA has been widely used for the secondary prevention of cerebro-and cardio-vascular diseases. However, this useful drug has detrimental effect not only on gastric mucosa but also on small intestinal mucosa. (30) The mechanism by which ASA induces small intestinal mucosa is not clear yet. However the first step of this phenomenon seems to be the increased mucosal permeability. (31, 32) Recently, we reported that low concentration of ASA, which does not induce cell death, increases intestinal epithelial cell permeability as assessed by trans-epithelial electric resistance and dextran flux through para-cellular pathway. (33) Moreover, ASA increases the production of reactive oxygen species in the epithelium, which induces the oxidative modification of ZO-1 protein between epithelial cells. By this result, we concluded that ASA could modify the function of tight junction via oxidative stress dependent mechanism. Our preliminary data suggested that drugs that has an anti-oxidant effects might be useful for the prevention of ASA-induced small intestinal epithelial cell permeability (data not shown).
The therapy and the prevention of NSAID induced small intestinal damage
The first choice of the treatment for NSAID-induced small intestinal damage is to stop taking NSAID. However NSAID are usually administered to the patients with chronic pain or chronic inflammatory diseases, and stopping these medicines is impossible in many cases.
At the beginning, many people investigated the adverse effect of low-toxic NSAID on small intestine. COX-2 selective NSAID have been reported to cause less damage than non-COX-selective NSAID on small intestine. (8) However, two recent reports have described that there are no differences in the incidence of small intestinal mucosal damage between COX-2 selective NSAID and traditional non-COX-selective NSAID. (9, 34) Afterwards, several drugs had been reported to be useful for the therapy and the prevention of NSAID-induced small intestinal injury in animal experiments, and therefore they were expected to be useful in clinical settings, however, only a few drugs has a potential.
Muco-protective prostaglandin analog, misoprostol, that has anti-inflammatory effects, has been also reported to decrease the indomethacin-induced small intestinal mucosal damage via its anti chemotactic effect for neutrophils. (35, 36) However these PGE2 drugs have often shows unfavorable side effects such as diarrhea, abdominal pain, or bloating and therefore not suitable for the long use.
The efficacy of sulfasalazine on the NSAID-induced small intestinal damage has been reported, (37) which is a sulfa drug that has anti-inflammatory effects and is commonly used in the treatment of inflammatory bowel disease as well as for rheumatoid arthritis. However, the effect of sulfasalazin were indirectly assessed by blood loss from intestinal wall and therefore should be re-examined by direct observation by VCE or BAE.
As described above, several studies suggested the usefulness of anti-biotics such as metronidazole (18) and ampicillin, (26) however, since in these studies mucosal damage was assessed by measuring mucosal permeability, the clinical usefulness of anti-biotics should be further elucidated. In addition, the usage of anti-biotics may have a limitation: long-term combination therapy with metronidazole and NSAID may lead to the appearance of resistant bacteria, and long time use of ampicillin sometimes causes diarrhea. Therefore, small intestine-specific agents that can be safely used for a long period such as gastric muco-protective drugs are anticipated.
Recent clinical data have shown the usefulness of mucoprotective drugs, rebamipide, on NSAID-induced small intestinal injury. (38) In this prospective, randomized, double-blinded, placebocontrolled and cross-over study, they found that rebamipide administered with omeprazole has protective effect on NSAIDinduced small intestinal injury in healthy volunteer by using VCE. This combination therapy might have a potential and further studies are now performed in our group to confirm the efficacy of this therapy. As described above, our group recently reported that NSAID induces ROS-dependent apoptosis of intestinal epithelial cells (19, 20) and ROS-dependent increase of intestinal epithelial cell permeability. (33) We also found that polaprezinc (PZ), a gastric muco-protective drugs, has a protective effect on NSAIDinduced apoptosis of small intestinal epithelial cells, (39) partly because ROS quenching mechanism of PZ as shown in gastric mucosa. (40) (41) (42) Since, in the United States, PZ, a chelating compound consisting of zinc and L-carnosine, is commercially available as a dietary supplement and in Japan PZ is commonly employed as an agent for the treatment of gastric ulcers, we think PZ might be a suitable drug for the treatment of NSAID-induced small intestinal injury.
It is well-known that proton pump inhibitors (PPI) are useful for the treatment of NSAID-induced gastric mucosal damage by its strong anti gastric acid secretion effect, and we have reported that PPI has anti-inflammatory effects, such as the inhibition of interleukin-8 production from vascular endothelial cells and gastric epithelial cells and subsequent chemotaxis of neutrophils. (43) In addition, we and another groups have described the protective effect of PPI on NSAID-induced small intestinal injury in the animal experiment. (44, 45) Therefore PPI has been expected to be a useful drug for the treatment of NSAID-induced small intestinal injury in the clinical field, however, Goldstein et al. (8) has reported that omeprazole, a PPI, could not prevent NSAIDinduced small intestinal injury in healthy volunteers. Although the effectiveness of PPI might be not high in acid-free environment, another PPI, lansoprazole (LPZ), might have a possibility; Takagi et al. (46) in our group have reported that LPZ can induce heme oxygenase-1 (HO-1) and this induction might ameliorate NSAIDinduced small intestinal injury. There are no comparative studies in regard to the effect of several PPIs on NSAID-induced small intestinal injury, and clinical trial should be performed to determine whether PPIs are effective or not for the treatment or prevention of NSAID-induced small intestinal injury. In addition, we should determine whether LPZ is suitable for the long use to treat or prevent NSAID-induced small intestinal injury, since LPZ has been reported to cause collagenous colitis in some patients. (47) (48) (49) The effect of PPI should also be evaluated because Wallace et al. (50) reported that PPI exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. This issue should be further examined.
Concluding remarks
In aging societies, the problem of NSAID-induced gastrointestinal damage will become more and more important. And NSAID affects entire gastrointestinal tract, not only small intestine but also stomach and colon, and cause unfavorable symptoms and side effects from epigastric discomfort to mucosal bleeding. Sometimes NSAID cause life threatening side effects without any symptoms in elderly patients. Therefore, agents that can be safely used for the treatment of "pan-gastrointestinal tract" in the patients with NSAID medication for a long period are anticipated.
Since many NSAID users are waiting for the appearance of safety muco-protective drugs, the most important thing for us is to clarify the precise mechanism by which NSAID induce small intestinal damage as soon as possible, and that clarified mechanisms will give us great hints to find novel strategies for preventing NSAID induced small intestinal damage.
